Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer

Article Economics

Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States

Raquel Aguiar-Ibanez et al.

Summary: This study evaluated the cost-effectiveness of Pembrolizumab as a first-line treatment for MSI-H/dMMR CRC patients and concluded that Pembrolizumab is highly cost-effective.

JOURNAL OF MEDICAL ECONOMICS (2022)

Add to Collection

Article Oncology

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

Luis A. Diaz et al.

Summary: The final overall survival analysis of the KEYNOTE-177 study showed that while pembrolizumab continued to demonstrate durable antitumor activity and fewer treatment-related adverse events compared to chemotherapy in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer, there was no statistically significant difference in overall survival between the two treatment groups.

LANCET ONCOLOGY (2022)

Add to Collection

Review Medicine, General & Internal

Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review

Leah H. Biller et al.

Summary: Colorectal cancer is the third most common cause of cancer mortality worldwide. For patients diagnosed with metastatic colorectal cancer, approximately 70% to 75% can survive beyond 1 year. Tailoring treatments based on the molecular and pathologic features of the tumor has shown to improve overall survival rates.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020

Wei Cao et al.

Summary: This study summarized the recent changing profiles of cancer burden worldwide and in China, revealing that breast cancer became the most diagnosed cancer globally in 2020. China accounted for 24% of newly diagnosed cases and 30% of cancer-related deaths worldwide in 2020, with a high cancer mortality rate.

CHINESE MEDICAL JOURNAL (2021)

Add to Collection

Article Pharmacology & Pharmacy

Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer

Chongqing Tan et al.

Summary: The study compared the health and economic outcomes of three treatment strategies in MSI-H/dMMR advanced colorectal cancer patients. It was found that first-line use of Pembrolizumab was more effective and cost-effective than chemotherapy.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Oncology

Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial

Thierry Andre et al.

Summary: The KEYNOTE-177 study found that pembrolizumab monotherapy significantly improved progression-free survival in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer compared to chemotherapy as first-line treatment, with clinically meaningful benefits. Health-related quality of life analyses further supported these findings.

LANCET ONCOLOGY (2021)

Add to Collection

Article Economics

Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China

Xin Guan et al.

Summary: In the Chinese healthcare perspective, fruquintinib is a cost-effective choice as the third-line treatment for mCRC patients compared to regorafenib, leading to cost savings and a slight decrease in QALYs.

JOURNAL OF MEDICAL ECONOMICS (2021)

Add to Collection

Meeting Abstract Oncology